NASDAQ:ZEAL

Zealand Pharma A/S Competitors

$32.79
+0.70 (+2.18 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.69
Now: $32.79
$32.85
50-Day Range
$29.52
MA: $31.87
$35.13
52-Week Range
$29.43
Now: $32.79
$44.42
Volume1,527 shs
Average Volume13,896 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19

Competitors

Zealand Pharma A/S (NASDAQ:ZEAL) Vs. SRPT, ALLK, BPMC, PRGO, SDGR, and GLPG

Should you be buying ZEAL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Zealand Pharma A/S, including Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), and Galapagos (GLPG).

Sarepta Therapeutics (NASDAQ:SRPT) and Zealand Pharma A/S (NASDAQ:ZEAL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Sarepta Therapeutics and Zealand Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Zealand Pharma A/S-214.31%-38.34%-30.40%

Earnings & Valuation

This table compares Sarepta Therapeutics and Zealand Pharma A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million15.50$-715,080,000.00($9.71)-7.65
Zealand Pharma A/S$6.20 million229.53$-85,670,000.00($2.54)-12.91

Zealand Pharma A/S has lower revenue, but higher earnings than Sarepta Therapeutics. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of Zealand Pharma A/S shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Sarepta Therapeutics and Zealand Pharma A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191202.50
Zealand Pharma A/S00203.00

Sarepta Therapeutics currently has a consensus price target of $150.4762, suggesting a potential upside of 104.59%. Zealand Pharma A/S has a consensus price target of $43.00, suggesting a potential upside of 31.14%. Given Sarepta Therapeutics' higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than Zealand Pharma A/S.

Volatility and Risk

Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Summary

Sarepta Therapeutics beats Zealand Pharma A/S on 9 of the 14 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Zealand Pharma A/S (NASDAQ:ZEAL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Institutional & Insider Ownership

65.4% of Allakos shares are owned by institutional investors. Comparatively, 4.3% of Zealand Pharma A/S shares are owned by institutional investors. 44.8% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Allakos and Zealand Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Zealand Pharma A/S-214.31%-38.34%-30.40%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Allakos and Zealand Pharma A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
Zealand Pharma A/S00203.00

Allakos currently has a consensus price target of $181.50, suggesting a potential upside of 67.64%. Zealand Pharma A/S has a consensus price target of $43.00, suggesting a potential upside of 31.14%. Given Allakos' higher probable upside, analysts plainly believe Allakos is more favorable than Zealand Pharma A/S.

Risk and Volatility

Allakos has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Valuation & Earnings

This table compares Allakos and Zealand Pharma A/S's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-57.42
Zealand Pharma A/S$6.20 million229.53$-85,670,000.00($2.54)-12.91

Allakos has higher earnings, but lower revenue than Zealand Pharma A/S. Allakos is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Allakos beats Zealand Pharma A/S on 9 of the 12 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Volatility & Risk

Zealand Pharma A/S has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Earnings and Valuation

This table compares Zealand Pharma A/S and Blueprint Medicines' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zealand Pharma A/S$6.20 million229.53$-85,670,000.00($2.54)-12.91
Blueprint Medicines$66.51 million85.25$-347,690,000.00($7.27)-13.46

Zealand Pharma A/S has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zealand Pharma A/S and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zealand Pharma A/S-214.31%-38.34%-30.40%
Blueprint Medicines41.08%43.72%33.35%

Insider & Institutional Ownership

4.3% of Zealand Pharma A/S shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Zealand Pharma A/S and Blueprint Medicines, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zealand Pharma A/S00203.00
Blueprint Medicines06812.67

Zealand Pharma A/S currently has a consensus price target of $43.00, indicating a potential upside of 31.14%. Blueprint Medicines has a consensus price target of $112.40, indicating a potential upside of 15.00%. Given Zealand Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts clearly believe Zealand Pharma A/S is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Zealand Pharma A/S on 8 of the 15 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Profitability

This table compares Zealand Pharma A/S and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zealand Pharma A/S-214.31%-38.34%-30.40%
Perrigo-0.13%9.78%4.92%

Risk & Volatility

Zealand Pharma A/S has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Insider & Institutional Ownership

4.3% of Zealand Pharma A/S shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Zealand Pharma A/S and Perrigo's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zealand Pharma A/S$6.20 million229.53$-85,670,000.00($2.54)-12.91
Perrigo$4.84 billion1.12$146.10 million$4.0310.07

Perrigo has higher revenue and earnings than Zealand Pharma A/S. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Zealand Pharma A/S and Perrigo, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zealand Pharma A/S00203.00
Perrigo04102.20

Zealand Pharma A/S presently has a consensus price target of $43.00, indicating a potential upside of 31.14%. Perrigo has a consensus price target of $52.00, indicating a potential upside of 28.08%. Given Zealand Pharma A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Zealand Pharma A/S is more favorable than Perrigo.

Summary

Perrigo beats Zealand Pharma A/S on 8 of the 14 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zealand Pharma A/S and Schrödinger, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zealand Pharma A/S00203.00
Schrödinger01302.75

Zealand Pharma A/S presently has a consensus price target of $43.00, indicating a potential upside of 31.14%. Schrödinger has a consensus price target of $85.50, indicating a potential upside of 9.28%. Given Zealand Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Zealand Pharma A/S is more favorable than Schrödinger.

Profitability

This table compares Zealand Pharma A/S and Schrödinger's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zealand Pharma A/S-214.31%-38.34%-30.40%
Schrödinger-19.92%-7.25%-5.33%

Insider and Institutional Ownership

4.3% of Zealand Pharma A/S shares are owned by institutional investors. Comparatively, 41.3% of Schrödinger shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Zealand Pharma A/S and Schrödinger's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zealand Pharma A/S$6.20 million229.53$-85,670,000.00($2.54)-12.91
Schrödinger$85.54 million64.04$-24,570,000.00N/AN/A

Schrödinger has higher revenue and earnings than Zealand Pharma A/S.

Summary

Schrödinger beats Zealand Pharma A/S on 7 of the 10 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Insider and Institutional Ownership

4.3% of Zealand Pharma A/S shares are held by institutional investors. Comparatively, 11.2% of Galapagos shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Zealand Pharma A/S has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Zealand Pharma A/S and Galapagos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zealand Pharma A/S00203.00
Galapagos210502.18

Zealand Pharma A/S currently has a consensus target price of $43.00, indicating a potential upside of 31.14%. Galapagos has a consensus target price of $143.7273, indicating a potential upside of 75.38%. Given Galapagos' higher possible upside, analysts plainly believe Galapagos is more favorable than Zealand Pharma A/S.

Profitability

This table compares Zealand Pharma A/S and Galapagos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zealand Pharma A/S-214.31%-38.34%-30.40%
Galapagos-70.67%-11.78%-5.58%

Valuation and Earnings

This table compares Zealand Pharma A/S and Galapagos' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zealand Pharma A/S$6.20 million229.53$-85,670,000.00($2.54)-12.91
Galapagos$1.00 billion5.36$167.83 million$5.4615.04

Galapagos has higher revenue and earnings than Zealand Pharma A/S. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Summary

Galapagos beats Zealand Pharma A/S on 11 of the 14 factors compared between the two stocks.


Zealand Pharma A/S Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$74.33+5.8%$5.56 billion$380.83 million-9.51
Allakos logo
ALLK
Allakos
1.7$108.52+3.7%$5.55 billionN/A-39.61
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$97.83+4.9%$5.39 billion$66.51 million18.05Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.5$40.60+1.1%$5.36 billion$4.84 billion-676.55
Schrödinger logo
SDGR
Schrödinger
1.3$78.24+3.5%$5.29 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$82.12+4.7%$5.13 billion$1.00 billion-12.44Analyst Report
Gap Down
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$54.08+5.8%$4.73 billionN/A0.00Analyst Report
Increase in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$76.24+4.5%$4.52 billionN/A-6.21Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.45+0.6%$4.31 billion$204.89 million-36.81
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.40+5.8%$4.20 billion$6.87 million-7.38Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$68.72+3.4%$4.01 billion$806.43 million-9.73Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.17+3.2%$3.88 billion$1.11 billion24.17Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$76.68+2.4%$3.66 billionN/A-21.85Analyst Report
News Coverage
Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.02+3.6%$3.62 billion$117.91 million-10.96Gap Down
I-Mab logo
IMAB
I-Mab
1.4$54.53+9.0%$3.57 billion$4.31 million-1.89Increase in Short Interest
Gap Down
LEGN
Legend Biotech
1.2$26.93+1.7%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.54+4.4%$3.41 billion$114.62 million-7.88Analyst Report
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.85+5.8%$3.40 billionN/A-6.04
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$49.29+4.0%$3.33 billion$306.98 million-7.05
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.77+5.4%$3.30 billion$339.08 million-12.66Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.04+3.8%$3.29 billion$36.13 million-73.19Unusual Options Activity
Gap Down
Insmed logo
INSM
Insmed
1.2$33.40+5.1%$3.27 billion$136.47 million-12.85
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.36+2.2%$3.13 billion$26.52 million-7.79
Alkermes logo
ALKS
Alkermes
1.2$19.59+3.7%$3.00 billion$1.17 billion-42.59
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$118.46+6.3%$3.00 billionN/A-58.94Gap Down
Arvinas logo
ARVN
Arvinas
1.5$65.00+5.6%$3.00 billion$42.98 million-25.39Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$70.30+2.9%$2.99 billion$421.03 million24.75Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.88+2.3%$2.94 billion$80.43 million108.96Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.52+1.5%$2.77 billion$644.77 million-10.49
OPKO Health logo
OPK
OPKO Health
1.9$4.24+2.6%$2.77 billion$901.90 million-23.55
Organogenesis logo
ORGO
Organogenesis
1.0$21.75+3.0%$2.70 billion$260.98 million-362.50
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.85+2.5%$2.61 billion$306.49 million25.67
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$45.13+6.8%$2.60 billionN/A-24.80
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.79+5.4%$2.51 billion$60,000.00-10.18
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$46.43+6.4%$2.50 billion$25 million-9.29
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.47+5.4%$2.50 billion$2.11 million-9.19Analyst Report
News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.30+9.6%$2.46 billion$182.24 million-8.96Analyst Upgrade
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$152.51+3.6%$2.44 billion$120.28 million-154.05Analyst Report
Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.36+0.1%$2.38 billion$33.94 million-90.28
Xencor logo
XNCR
Xencor
1.2$43.07+6.6%$2.33 billion$156.70 million-30.76News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.49+3.1%$2.30 billion$15 million-17.53Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.87+4.6%$2.29 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.17+0.3%$2.20 billion$963.01 million13.72News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$28.27+5.1%$2.05 billion$23.90 million-17.56Analyst Report
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.26+3.4%$2.00 billion$429.76 million-105.18News Coverage
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.92+3.9%$1.98 billion$410,000.00-6.29Analyst Report
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$54.52+5.2%$1.93 billionN/A-20.27
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$21.58+2.7%$1.92 billion$34.51 million-18.44
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$64.33+3.2%$1.91 billionN/A-27.37Increase in Short Interest
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.